Wyeth Licenses Interleukin Receptor Patents from ZymoGenetics
Business Review Editor
Abstract
Wyeth licensed two US patent applications for Interleukin-13 receptor subunit (IL-13R alpha2), also known as WSX-II, from ZymoGenetics. WSX-II is a naturally occurring decoy receptor, capable of binding the cytokine IL-13.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.